


SCOPE OF THE CLAIM

- 50-5
A2
1. Substituted benzylthiazolidine-2,4-dione derivatives represented by a general formula (1)




[wherein A denotes a phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is unsubstituted or may have substituents], their medicinally acceptable salts and their hydrates.

2. The substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of Claim 1, wherein A is phenyl group which is unsubstituted or may have substituents.
3. The substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of Claim 1, wherein A is phenoxy group which is unsubstituted or may have substituents.
4. The substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of Claim 1, wherein A is benzyloxy group which is unsubstituted or may have substituents.
5. A compound of Claim 1, being N-[(4-benzyloxyphenyl)-methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, its medicinally acceptable salts and its hydrates.

6. A compound of Claim 1, being N-[(4-phenoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, its medicinally acceptable salts and its hydrates.


7. A compound of Claim 1, being N-[(biphenyl-4-yl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, its medicinally acceptable salts and its hydrates.

8. A blood glucose-decreasing drug having at least one or more kinds of substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1)




[wherein A denotes a phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is unsubstituted or may have substituents], their medicinally acceptable salts and their hydrates as effective ingredients.

9. A lipid in blood-decreasing drug having at least one or more kinds of substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1)



[wherein A denotes a phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is

10. An agonistic drug of human peroxisome proliferator-activated receptor having at least one or more kinds of substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1)



[wherein A denotes a phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is unsubstituted or may have substituents], their medicinally acceptable salts and their hydrates as effective ingredients.

add

A2